info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report Information By Service (Pharmaceutical Manufacturing Services, Drug Development Services and Biologics Manufacturing Services), By End User (Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma and Other End Users) – United States Market Forecast Till 2032


ID: MRFR/HC/20199-HCR | 128 Pages | Author: Rahul Gotadki| December 2024

United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Overview


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size was valued at USD 46.27 Billion in 2023. The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market industry is projected to grow from USD 50.34 Billion in 2024 to USD 91.48 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.86% during the forecast period (2023 - 2032). Modern manufacturing methods and procedures, the expansion of the market for generic medications, and the significant use of small molecule medications for a variety of illnesses are the main market drivers expected to drive the United States industry for pharmaceutical contract development and manufacturing organizations (CDMOs).


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Overview


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Trends




  • Rising launch of efficient pharmaceutical solutions is driving the market growth




Pharmaceutical businesses are being encouraged to launch efficient pharmaceutical solutions to speed up the treatment process for the rising incidence of chronic diseases and the aging population in the US. The World Health Organization (WHO) predicts that by 2020, non-communicable diseases (NCDs) will account for 57% of the burden of disease. Additionally, the ability of CDMOs to streamline the pharmaceutical supply chain and the implementation of the one-stop-shop concept to introduce efficient drug goods into the market is anticipated to fuel the expansion of the CDMO market in the United States over the projected period. In the upcoming years, it is expected that the CDMO market CAGR will grow more rapidly in the United States due to the expanding therapeutic applications of biologics and the growing share of pipeline compounds.


In addition, the growth of the contract development and manufacturing organizations sector is anticipated to be fueled by rising infrastructure expenditures and the ability of United States CDMOs to offer completely integrated services through cutting-edge technologies. Due to the availability of cutting-edge R&D & production platforms and trained workers, the outsourcing of manufacturing processes to CDMOs has also resulted in rapid regulatory clearances in the United States. A lot of CDMOs are putting a lot of effort into capital investments in order to diversify geographically and create new compounds. October 2017 saw the announcement by CordenPharma International of a strategic €3.7 million investment in their Swiss small molecule API production facility. Additionally, one of the main factors expected to drive the expansion of the CDMO market throughout the projected period is the augmentation of the number of new entrants via partnerships.


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segment Insights




  • United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Service Insights




The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on Service, includes Pharmaceutical Manufacturing Services, Drug Development Services, and Biologics Manufacturing Services. The pharmaceutical manufacturing services segment held a substantial stake, which may be attributable to factors including the growing demand for biologics and biosimilars in the region, as well as the expanding pharmaceutical and biopharmaceutical industries worldwide. Additionally, major industry participants are spending money on drug development and discovery, which is expected to fuel the segment's expansion.


Figure 1: United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, by Service, 2022 & 2032 (USD Billion)


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, by Service, 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review        


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) End User Insights


The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on End User, includes Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma, and Other End Users. Throughout the projection period, the big pharma category is anticipated to have the highest CAGR. Some of the key factors expected to propel the market's growth are increased investment in the big pharma firms of gene and cell therapies, a rise in the number of biologics undergoing pipeline investigations, and the growing demand for targeted medication therapy.


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Country Insights


For small and mid-sized pharmaceutical companies, the process of finding and developing new drugs is extremely costly and time-consuming. Nonetheless, drug development activities are outsourced to contract development and research groups by pharmaceutical companies, who choose this more cost-effective and efficient approach in the US. Serious repercussions are incurred by the company, and the brand name when guidelines and regulations are not followed by the appropriate authorities and defective pharmaceuticals are produced. As a result, in the pharmaceutical sector, following regulatory requirements is crucial. Major pharmaceutical corporations in the United States are also restocking the market with increased investments in this area. In order to satisfy market and outsourcing demand, the United States contract manufacturing organizations, or CMOs, have expanded from their original provision of basic manufacturing services to a broad package of services.


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Key Market Players & Competitive Insights


Leading market players are putting more on R&D to increase the range of products they offer, which will support the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market's expansion. In addition, market players are engaging in a range of calculated initiatives to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry must provide reasonably priced goods.


Major players in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market are engaging in research and development activities in an effort to boost market demand includes Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).


Key Companies in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market include



  • Thermo Fisher Scientific Inc. (US)

  • Catalent (US)

  • Lonza Group (Switzerland)

  • Recipharm AB (Sweden)

  • Vetter Pharma International GMBH (Germany)

  • FAMAR Health Care Services (Greece)

  • AbbVie (US)

  • Aenova Group (Germany)

  • Consort Medical (UK)

  • Almac Group (UK)

  • Siegfried Holding AG (Switzerland)

  • Boehringer Ingelheim International GmbH (Germany)

  • Evonik Industries AG (Germany)


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Industry Developments


February 2022: Recipharm AB (Sweden) purchased Arranta Bio (U.S.) in order to expand its service offerings and establish a solid foothold in the U.S. by providing scientifically distinct contract research and manufacturing services for ATMPs.


February 2021: Charles River Laboratories International, Inc. (United States) paid $875 million to Cognate BioServices, Inc. (United States) to expand their capabilities in cell and gene therapy CDMOs.


February 2020: MaSTherCell Global Inc. (Belgium) was purchased by Catalent Inc. (U.S.) for $315 million with the intention of utilizing MaSTherCell's distinctive portfolio of technologies, capabilities, and associated analytical services to lead the field with its cell & genetic therapy platforms.


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Service Outlook



  • Pharmaceutical Manufacturing Services

  • Drug Development Services

  • Biologics Manufacturing Services


United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) End User Outlook



  • Small & Mid-Size Pharma

  • Generic Pharmaceutical Companies

  • Big Pharma

  • Other End Users

Report Attribute/Metric Details
Market Size 2023 USD 46.27Billion
Market Size 2024 USD 50.34Billion
Market Size 2032 USD 97.07 Billion
Compound Annual Growth Rate (CAGR) 6.86% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018-2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, Distribution Channel, and Region
Countries Covered United States
Key Companies Profiled Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany)
Key Market Opportunities ·         High expense of developing drugs in-house is probably going to fuel market expansion. ·         Rising demand for pharmaceutical products will fuel growth.
Key Market Dynamics ·         Increase in strategic alliances and investments to support CDMOs, or contract development and manufacturing organizations ·         Growing biologics therapeutic applications and a larger proportion of pipeline compounds are expected to fuel the CDMO sector's growth in the upcoming years.


Frequently Asked Questions (FAQ) :

In 2022, the pharmaceutical contract development and manufacturing organization (CDMMO) market in the United States was estimated to be worth USD 46.27 billion.

From 2023 to 2032, the market is expected to expand at a compound annual growth rate (CAGR) of 6.86%.

AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), and Thermo Fisher Scientific Inc. (US) are the major players in the market.

In 2022, the market was dominated by the Pharmaceutical Manufacturing Services segment.

The market share that the Big Pharma category held was the highest.

Leading companies partner with us for data-driven Insights.

client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.